ICER Embarks on Annual Assessment of Insurance Coverage
The Institute for Clinical and Economic Review (ICER) is holding a review of current coverage policies of US insurers and [...]
ICER Publishes White Paper on Fair Patient Access to Prescription Drugs
The Institute for Clinical and Economic Review (ICER) published a new white paper entitled: "Cornerstones of 'Fair' Drug Coverage: Appropriate [...]
Educating the Next Leaders in Applied HEOR: Jefferson’s Unique Approach
Online education for the working professional is experiencing exponential growth. In the field of Health Economics and Outcomes Research (HEOR), [...]
[Webinar] How Can Adaptive Designs and Master Protocols Enhance Your Oncology Trials?
While oncology trials comprise a large proportion of current research pipelines, conventional oncology development programs are frequently expensive, inefficient, and [...]
ICER Condemns Monopoly Pricing of Trikafta Despite High Marks for Efficacy
While the therapeutic value of Vertex Pharmaceuticals’ triplet drug Trikafta for cystic fibrosis is indisputable, the Institute for Clinical and [...]
COVID-19 Underscores Urgent Need for Real-world Data
In this video, Nigel Hughes, Scientific Director RWD/RWE at Janssen Research and Development, discusses some of the challenges and opportunities [...]
Highmark Enters Outcomes-based Contract for Anti-inflammatory Drug Cimzia
Highmark announced today that it entered into an outcomes-based agreement with UCB Inc. for its tumor necrosis factor blocking medication [...]
Extracting Maximum Value from Health Spending
From 1990 thru 2015, the United States experienced a 3.3 -year increase in life expectancy. In a recently published study, [...]
A Little More Spending Is Not the End of the World
Investigating the drivers of healthcare spending is the underlying goal of Going Below The Surface. An article published last month in [...]
[Webinar] Demystifying and Applying Artificial Intelligence to Scientific Research
Tune in to this webinar on the state of AI in literature-based research on Wednesday, October 14 at 1:00pm EDT [...]
The Importance of RWE in FDA Approvals
RWE is now helping the U.S. Food and Drug Administration (FDA) to approve more drugs than ever. In 2019, RWE [...]
Inovalon Announces Launch of Inovalon DataStream™ API
Today, Inovalon announced the launch of its Inovalon DataStream™ API which will allow cloud-based, traditional enterprises or mobile app software [...]
[DIA Recorded Event] Modernizing Regulatory Evidence With Real World Studies
Real world evidence (RWE) is making a larger impact on healthcare across the product lifecycle. Meeting stakeholder requirements requires impactful [...]
[Webinar] Innovative Approaches to Generate Real World Evidence (RWE)
Real world evidence (RWE) is making a larger impact on healthcare across the product lifecycle. Meeting stakeholder requirements requires impactful [...]
AHRQ’s Registries User Guide Gets A New Edition
Today the U.S. Agency for Healthcare Research and Quality (AHRQ) released an updated version of "Registries for Evaluating Patient Outcomes: [...]
[Webinar] Open Source Models in HEOR: Benefits, Challenges, and ISPOR Members’ Perceptions.
Use of open source models (OSMs) for cost-effectiveness analysis is an area of increasing interest. On Thursday, September 24, 2020 [...]
FDA Proposes Rule Change for Off-label Marketing
A proposed rule clarifying when manufacturers would have to update product labeling to reflect unapproved uses of their medicines has [...]
CVS Health’s Value Constrained by Politics
Market analysts believe that CVS Health’s (NYSE:CVS) stock price is poised to do well in the event of a Biden [...]
Methodological Considerations in Economic Evaluations of Gene Therapies
Researchers recently performed a study aiming to identify methodological considerations in the research literature addressing economic evaluations (EEs) of gene [...]
Patient Centricity—Exploring the Patient Dynamic From Different Perspectives
Previously, the culture of clinical research was primarily directed by researchers. Now it is increasingly driven by the needs of [...]
Harnessing the Power of Precision Medicine to Combat COVID-19
Precision medicine aims to provide the right treatment at the right time for every patient. This means improved diagnostic accuracy, [...]
The ISPOR Health Economics and Outcomes Research Competencies Framework
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) has established a set of 41 competencies for HEOR professionals organized [...]
How to Excel at Next Generation Trial Execution
The coming generation of clinical trials will be quicker, more efficient, and result in better patient outcomes. As the COVID-19 [...]
States Push for Adoption of Canadian Drug Prices
States are now trying to import Canadian drug prices rather than Canadian prescription drugs. Model legislation drafted by the National [...]
Free Registration for Virtual ISPOR-FDA Summit 2020
Regulatory decision making for medical devices is becoming increasingly dependent on patient-preference information (PPI).This virtual Summit will provide a forum [...]